Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
Identifieur interne : 002939 ( Main/Exploration ); précédent : 002938; suivant : 002940Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
Auteurs : Kurt Jellinger [Autriche] ; Harald Bliesath [Allemagne]Source :
- Journal of Neurology [ 0340-5354 ] ; 1987-06-01.
Abstract
Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.
Url:
DOI: 10.1007/BF00314280
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name></author><author><name sortKey="Bliesath, Harald" sort="Bliesath, Harald" uniqKey="Bliesath H" first="Harald" last="Bliesath">Harald Bliesath</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:736AE8781BD70ADB7075C0C3EF16996111DBDE1B</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1007/BF00314280</idno><idno type="url">https://api.istex.fr/document/736AE8781BD70ADB7075C0C3EF16996111DBDE1B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A45</idno><idno type="wicri:Area/Main/Curation">000913</idno><idno type="wicri:Area/Main/Exploration">002939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo</title><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann Institute of Clinical Neurobiology and Department of Neurology, Lainz Hospital, Wolkersbergenstrasse 1, A-1130, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Bliesath, Harald" sort="Bliesath, Harald" uniqKey="Bliesath H" first="Harald" last="Bliesath">Harald Bliesath</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Byk Gulden Research Center, D-7750, Konstanz</wicri:regionArea><wicri:noRegion>Konstanz</wicri:noRegion><wicri:noRegion>Konstanz</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="ISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1987-06-01">1987-06-01</date><biblScope unit="volume">234</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="280">280</biblScope><biblScope unit="page" to="282">282</biblScope></imprint><idno type="ISSN">0340-5354</idno></series><idno type="istex">736AE8781BD70ADB7075C0C3EF16996111DBDE1B</idno><idno type="DOI">10.1007/BF00314280</idno><idno type="ArticleID">Art2</idno><idno type="ArticleID">BF00314280</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-5354</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Budipine, a new 4,4-diphenylpiperidine derivative, and placebo were administered three times daily to 31 patients with Parkinson's disease over a period of 12 weeks. All patients in the two treatment groups received levodopa (plus benserazide) at an optimum and constant dose for at least 2 months before the start of the study and throughout the trial. The additional administration of budipine (daily dose 60 mg) was excellently tolerated by 14 patients, while 2 patients left the study because of mental confusion at an early stage of the trial. The budipine group showed a 22% improvement on the Columbia Rating Scale (median score). Compared with the placebo group (4% improvement), there was a highly significant difference (P<0.01, one-tailed test). Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity. Owing to its long half-life (31 h) with little plasma level fluctuations, budipine appears to be an effective agent in the treatment of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name></region></country><country name="Allemagne"><noRegion><name sortKey="Bliesath, Harald" sort="Bliesath, Harald" uniqKey="Bliesath H" first="Harald" last="Bliesath">Harald Bliesath</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:736AE8781BD70ADB7075C0C3EF16996111DBDE1B
|texte= Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo
}}
| This area was generated with Dilib version V0.6.23. |  |